|1.||Falck, John R: 5 articles (01/2014 - 12/2004)|
|2.||Zeng, Xiang-Jun: 2 articles (11/2012 - 01/2011)|
|3.||Wang, Hong-Xia: 2 articles (11/2012 - 01/2011)|
|4.||Zhang, Li-Ke: 2 articles (11/2012 - 01/2011)|
|5.||Zhang, Dong-Mei: 2 articles (11/2012 - 01/2011)|
|6.||Lu, Ling-Qiao: 2 articles (11/2012 - 01/2011)|
|7.||Barbosa-Sicard, Eduardo: 2 articles (03/2008 - 12/2005)|
|8.||Michaelis, U Ruth: 2 articles (03/2008 - 12/2005)|
|9.||Fleming, Ingrid: 2 articles (03/2008 - 12/2005)|
|10.||Hammock, Bruce D: 2 articles (12/2007 - 09/2004)|
09/03/2004 - "Perfusion with the selective P450 epoxygenase inhibitor N-methylsulphonyl-6-(2-proparglyloxyphenyl)hexanamide (MS-PPOH) for 20 minutes before ischemia results in reduced postischemic LVDP recovery in WT hearts and abolishes the improved postischemic LVDP recovery in CYP2J2 Tr hearts. "
12/01/2004 - "Rats treated with MIC, 17-ODYA and DDMS, but not MS-PPOH, produced comparable reductions in infarct size when administered prior to ischemia or reperfusion compared to vehicle. "
12/01/2004 - "Groups received either miconazole (MIC, non-selective CYP inhibitor, 3 mg/kg), 17-octadecynoic acid (17-ODYA, CYP omega-hydroxylase inhibitor, 0,3 or 3 mg/kg), N-methylsulfonyl-12, 12-dibromododec-11-enamide (DDMS, CYP omega-hydroxylase inhibitor, 0,4 or 4 mg/kg), N-methanesulfonyl-6-(2-propargyloxyphenyl)hexanamide (MS-PPOH, CYP epoxygenase inhibitor, 3 mg/kg), or vehicle either 10 minutes prior to ischemia or 5 minutes prior to reperfusion. "
11/01/2012 - "Neonatal rat cardiomyocytes underwent 3-h hypoxia followed by 2-, 5-, or 6-h reoxygenation (H/R) or three cycles of 5-min reoxygenation followed by 5-min hypoxia before 90-min reoxygenation (HPost); or were transfected with pcDNA3.1-CYP2J3 for 48 h before H/R; or were treated with MS-PPOH for 10 min before HPost. "
12/01/2005 - "In Transwell assays, the migration of endothelial cells pre-exposed to hypoxia to increase CYP expression was abolished by CYP 2C antisense oligonucleotides as well as by the CYP inhibitor MS-PPOH and the EET antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (EEZE). "
03/01/2008 - "Moreover, endothelial cells preexposed to hypoxia demonstrated an increase in serum-induced cell migration that was sensitive to the CYP2C inhibitors sulfaphenazole and MS-PPOH and the EET antagonist 14,15-epoxyeicosa-5(Z)-enoic acid. "
|3.||Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
12/01/2007 - "Mice were administered a single intraperitoneal injection of AUDA-BE (10 mg/kg) or vehicle at 30 mins before 2-h middle cerebral artery occlusion (MCAO) or at reperfusion, in the presence and absence of P450 epoxygenase inhibitor N-methylsulfonyl-6-(2-propargyloxyphenyl) hexanamide (MS-PPOH). "
01/01/2011 - "Administration of MS-PPOH before ischaemia significantly decreased 11,12-EET synthesis in both IPC and IPost compared with I/R rats (2.1 ± 0.2, 3.2 ± 0.3 and 2.9 ± 0.2 ng/mg wet weight, respectively; P < 0.01), but decreased the cardioprotective effects, as evidenced by cardiac function and myocardial infarct size, of IPost only. "
|3.||RNA (Ribonucleic Acid)
|5.||12-(3-adamantan-1-ylureido)dodecanoic acid butyl ester
|6.||cytochrome P-450 omega-hydroxylase
|7.||cytochrome P-450 CYP2C subfamily